Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) Revenue
Annual & quarterly revenue history · segment & region breakdown
COLL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCollegium Pharmaceutical, Inc. trailing twelve-month (TTM) revenue is $0.80B, an increase of 23.62% year-over-year from $0.78B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.78B | +$0.15B | +23.62% |
| 2024-12-31 | $0.63B | +$0.06B | +11.41% |
| 2023-12-31 | $0.57B | +$0.10B | +22.17% |
| 2022-12-31 | $0.46B | +$0.19B | +67.56% |
| 2021-12-31 | $0.28B | -$0.03B | -10.69% |
| 2020-12-31 | $0.31B | +$0.01B | +4.49% |
| 2019-12-31 | $0.30B | +$0.02B | +5.81% |
| 2018-12-31 | $0.28B | +$0.25B | +884.73% |
| 2017-12-31 | $0.03B | +$0.03B | +1564.29% |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare COLL revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Collegium Pharmaceutical, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Collegium Pharmaceutical, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Collegium Pharmaceutical, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
COLL revenue · 4 questionsCOLL's trailing twelve-month (TTM) revenue is $0.80B. That is an increase of 23.62% year-over-year from $0.78B in FY2025.
▸ Source: FMP · Collegium Pharmaceutical, Inc. SEC filings · GAAP · Collegium Pharmaceutical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026